Moderna

BIOLOGICAL2 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, DHR Health Institute for Research and Development

Conditions

Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second DoseCOVID-19SARS CoV 2 Infection

Phase 2

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

DHR Health Institute for Research and DevelopmentCOVID-19, SARS CoV 2 Infection

Start: 2021-07-30End: 2023-08-31Target: 1000Updated: 2022-03-29

Unknown Phase

Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine

Assistance Publique - Hôpitaux de ParisAdult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose

Start: 2021-05-28End: 2022-01-31Updated: 2021-08-03

Related Papers

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial.

2022-05-128 citations